Hunter C. Smith - 09 Feb 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Financial Officer
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith
Issuer symbol
RYTM
Transactions as of
09 Feb 2025
Net transactions value
-$74,533
Form type
4
Filing time
11 Feb 2025, 21:44:16 UTC
Previous filing
04 Feb 2025
Next filing
14 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +4,062 +4% 105,248 09 Feb 2025 Direct F1
transaction RYTM Common Stock Options Exercise +2,343 +2.2% 107,591 11 Feb 2025 Direct F1
transaction RYTM Common Stock Sale $74,245 -1,291 -1.2% $57.51 106,300 11 Feb 2025 Direct F2
transaction RYTM Common Stock Sale $288 -5 -0% $57.53 106,295 11 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -4,062 -50% $0.000000 4,062 09 Feb 2025 Common Stock 4,062 Direct F1, F3
transaction RYTM Restricted Stock Units Options Exercise $0 -2,343 -100% $0.000000 0 11 Feb 2025 Common Stock 2,343 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
F4 The restricted stock units vest or have vested as to 25% of the total shares on each of February 11 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.